Background and objectives: Streptococcus pneumoniae urinary antigen (u-Ag) testing has recently gained attention in the early diagnosis of severe and critical acute respiratory syndrome coronavirus-2/pneumococcal co-infection. The aim of this study is to assess the effectiveness of Streptococcus pneumoniae u-Ag testing in coronavirus disease 2019 (COVID-19) patients, in order to assess whether pneumococcal co-infection is associated with different mortality rate and hospital stay in these patients. Materials and Methods: Charts, protocols, mortality, and hospitalization data of a consecutive series of COVID-19 patients admitted to a tertiary hospital in northern Italy during COVID-19 outbreak were retrospectively reviewed. All patients underwent Streptococcus pneumoniae u-Ag testing to detect an underlying pneumococcal co-infection. Covid19+/u-Ag+ and Covid19+/u-Ag-patients were compared in terms of overall survival and length of hospital stay using chi-square test and survival analysis. Results: Out of 575 patients with documented pneumonia, 13% screened positive for the u-Ag test. All u-Ag+ patients underwent treatment with Ceftriaxone and Azithromycin or Levofloxacin. Lopinavir/Ritonavir or Darunavir/Cobicistat were added in 44 patients, and hydroxychloroquine and low-molecular-weight heparin (LMWH) in 47 and 33 patients, respectively. All u-Ag+ patients were hospitalized. Mortality was 15.4% and 25.9% in u-Ag+ and u-Ag-patients, respectively (p = 0.09). Survival analysis showed a better prognosis, albeit not significant, in u-Ag+ patients. Median hospital stay did not differ among groups (10 vs. 9 days, p = 0.71). Conclusions: The routine use of Streptococcus pneumoniae u-Ag testing helped to better target antibiotic therapy with a final trend of reduction in mortality of u-Ag+ COVID-19 patients having a concomitant pneumococcal infection. Randomized trials on larger cohorts are necessary in order to draw definitive conclusion.

Effectiveness of streptococcus pneumoniae urinary antigen testing in decreasing mortality of COVID-19 co-infected patients: A clinical investigation / A. Desai, O.G. Santonocito, G. Caltagirone, M. Kogan, F. Ghetti, I. Donadoni, F. Porro, V. Savevski, D. Poretti, M. Ciccarelli, F. Martinelli Boneschi, A. Voza. - In: MEDICINA. - ISSN 1010-660X. - 56:11(2020 Nov), pp. 572.1-572.10. [10.3390/medicina56110572]

Effectiveness of streptococcus pneumoniae urinary antigen testing in decreasing mortality of COVID-19 co-infected patients: A clinical investigation

F. Martinelli Boneschi;
2020

Abstract

Background and objectives: Streptococcus pneumoniae urinary antigen (u-Ag) testing has recently gained attention in the early diagnosis of severe and critical acute respiratory syndrome coronavirus-2/pneumococcal co-infection. The aim of this study is to assess the effectiveness of Streptococcus pneumoniae u-Ag testing in coronavirus disease 2019 (COVID-19) patients, in order to assess whether pneumococcal co-infection is associated with different mortality rate and hospital stay in these patients. Materials and Methods: Charts, protocols, mortality, and hospitalization data of a consecutive series of COVID-19 patients admitted to a tertiary hospital in northern Italy during COVID-19 outbreak were retrospectively reviewed. All patients underwent Streptococcus pneumoniae u-Ag testing to detect an underlying pneumococcal co-infection. Covid19+/u-Ag+ and Covid19+/u-Ag-patients were compared in terms of overall survival and length of hospital stay using chi-square test and survival analysis. Results: Out of 575 patients with documented pneumonia, 13% screened positive for the u-Ag test. All u-Ag+ patients underwent treatment with Ceftriaxone and Azithromycin or Levofloxacin. Lopinavir/Ritonavir or Darunavir/Cobicistat were added in 44 patients, and hydroxychloroquine and low-molecular-weight heparin (LMWH) in 47 and 33 patients, respectively. All u-Ag+ patients were hospitalized. Mortality was 15.4% and 25.9% in u-Ag+ and u-Ag-patients, respectively (p = 0.09). Survival analysis showed a better prognosis, albeit not significant, in u-Ag+ patients. Median hospital stay did not differ among groups (10 vs. 9 days, p = 0.71). Conclusions: The routine use of Streptococcus pneumoniae u-Ag testing helped to better target antibiotic therapy with a final trend of reduction in mortality of u-Ag+ COVID-19 patients having a concomitant pneumococcal infection. Randomized trials on larger cohorts are necessary in order to draw definitive conclusion.
No
English
Antibodies; Bacterial infection 2; COVID-19; SARS-CoV-2; Streptococcus pneumoniae
Settore MED/26 - Neurologia
Articolo
Sì, ma tipo non specificato
Pubblicazione scientifica
nov-2020
29-ott-2020
MDPI AG
56
11
572
1
10
10
Pubblicato
Periodico con rilevanza internazionale
scopus
crossref
wos
Aderisco
info:eu-repo/semantics/article
Effectiveness of streptococcus pneumoniae urinary antigen testing in decreasing mortality of COVID-19 co-infected patients: A clinical investigation / A. Desai, O.G. Santonocito, G. Caltagirone, M. Kogan, F. Ghetti, I. Donadoni, F. Porro, V. Savevski, D. Poretti, M. Ciccarelli, F. Martinelli Boneschi, A. Voza. - In: MEDICINA. - ISSN 1010-660X. - 56:11(2020 Nov), pp. 572.1-572.10. [10.3390/medicina56110572]
open
Prodotti della ricerca::01 - Articolo su periodico
12
262
Article (author)
si
A. Desai, O.G. Santonocito, G. Caltagirone, M. Kogan, F. Ghetti, I. Donadoni, F. Porro, V. Savevski, D. Poretti, M. Ciccarelli, F. Martinelli Boneschi...espandi
File in questo prodotto:
File Dimensione Formato  
medicina-56-00572.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 713.86 kB
Formato Adobe PDF
713.86 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/898051
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 14
  • OpenAlex ND
social impact